Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2020-01-17 Capital/Financing Update
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
S-3/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-3/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is a registration statement used for securities offerings, specifically a shelf registration allowing the company to offer up to $75 million of various securities including common stock, preferred stock, debt securities, warrants, and units. The document includes a prospectus and detailed information about the securities offering, risk factors, use of proceeds, and legal matters. It is not a financial report, earnings release, or management discussion, but rather a capital raising filing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or certification but the actual registration statement amendment filing.
2020-01-17 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement Amendment No. 1 filed with the SEC by Moleculin Biotech, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes details about the securities to be offered (common stock, preferred stock, debt securities, warrants, units), the registration process, and legal disclaimers. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement amendment, not just an announcement of a report. Hence, the classification is CAP with high confidence.
2020-01-17 English
8-K
Investor Presentation Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 13, 2020, by Moleculin Biotech, Inc. The key content is described under Item 7.01 as a Regulation FD Disclosure, which states that the company will use the presentation set forth as Exhibit 99.1 in meetings with the investment community. The exhibit is explicitly described as an "Investor Presentation dated January 2020." There is no detailed financial data or comprehensive report content within the text itself, only a reference to the presentation. The document length is 3668 characters, which is relatively short and consistent with an announcement or filing of a presentation rather than a full report. According to the classification rules, this type of document is best classified as an Investor Presentation (IP).
2020-01-13 English
SABBY 13G-A MBRX 1.07.20
Major Shareholding Notification
2020-01-08 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel responding to a comment letter from the SEC staff regarding the company's Registration Statement on Form S-3. It discusses amendments to the certificate of incorporation and disclosure updates to be made in the next Form 10-K filing. The document is a regulatory correspondence related to a registration statement and does not contain financial statements or detailed financial data. It is not a report itself but a regulatory filing responding to SEC comments. Therefore, it fits best under Regulatory Filings (RNS).
2020-01-07 English
Regulatory Filings 2020
Regulatory Filings
2020-01-06 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.